WO2024236361 - COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS
National phase entry is expected:
Publication Number
WO/2024/236361
Publication Date
21.11.2024
International Application No.
PCT/IB2024/000233
International Filing Date
15.05.2024
Title **
[English]
COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS
[French]
COMPOSITIONS ET PROCÉDÉS D'ADMINISTRATION D'ACIDES NUCLÉIQUES À DES CELLULES
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
1-1, Doshomachi 4-chome
Chuo-ku, Osaka-shi
Osaka, 541-0045, JP
Inventors
ALAM, Mohammad, Parvez
c/o Takeda Development Center Americas, Inc.
95 Hayden Avenue
Lexington, MA 02421, US
PADMASHALI, Roshan, Padmashali Manohara
c/o Takeda Development Center Americas, Inc.
95 Hayden Avenue
Lexington, MA 02421, US
Priority Data
63/466,639
15.05.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2229 | |
| EPO | Filing, Examination | 15176 | |
| Japan | Filing | 532 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 7435 |
Total: 25947 USD
Abstract[English]
The disclosure features novel lipid nanoparticle formulations and use thereof. Lipid nanoparticles include cationic ionizable lipids, helper lipids, sterols, and conjugated lipids. Lipid nanoparticles further including therapeutics and/or prophylactics such as DNA are useful in the delivery of therapeutics and/or prophylactics to cells or organs (e.g., mammalian cells or organs) to, for example, regulate polypeptide, protein, or gene expression.[French]
L'invention concerne de nouvelles formulations de nanoparticules lipidiques et leur utilisation. Les nanoparticules lipidiques comprennent des lipides ionisables cationiques, des lipides auxiliaires, des stérols et des lipides conjugués. Les nanoparticules lipidiques comprenant en outre des agents thérapeutiques et/ou prophylactiques tels que l'ADN sont utiles dans l'administration d'agents thérapeutiques et/ou prophylactiques à des cellules ou à des organes (par exemple, des cellules ou des organes de mammifère) pour, par exemple, réguler l'expression de polypeptides, de protéines ou de gènes.